Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report

Koji Kato, Shinya Hara, Jun ichi Kawada, Yoshinori Ito

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.

    Original languageEnglish
    Pages (from-to)879-881
    Number of pages3
    JournalJournal of Infection and Chemotherapy
    Volume21
    Issue number12
    DOIs
    Publication statusPublished - Dec 1 2015

    Fingerprint

    Central Nervous System Diseases
    valacyclovir
    Acyclovir
    Language Development Disorders
    Therapeutics
    Recurrence
    Human Herpesvirus 2
    Simplexvirus
    Cerebrospinal Fluid
    Neonatal herpes
    DNA
    Serum

    All Science Journal Classification (ASJC) codes

    • Microbiology (medical)
    • Pharmacology (medical)
    • Infectious Diseases

    Cite this

    Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy : Case report. / Kato, Koji; Hara, Shinya; Kawada, Jun ichi; Ito, Yoshinori.

    In: Journal of Infection and Chemotherapy, Vol. 21, No. 12, 01.12.2015, p. 879-881.

    Research output: Contribution to journalArticle

    @article{b77ab47c9ce84ffb88952a4f13822897,
    title = "Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report",
    abstract = "A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.",
    author = "Koji Kato and Shinya Hara and Kawada, {Jun ichi} and Yoshinori Ito",
    year = "2015",
    month = "12",
    day = "1",
    doi = "10.1016/j.jiac.2015.08.005",
    language = "English",
    volume = "21",
    pages = "879--881",
    journal = "Journal of Infection and Chemotherapy",
    issn = "1341-321X",
    publisher = "Elsevier BV",
    number = "12",

    }

    TY - JOUR

    T1 - Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy

    T2 - Case report

    AU - Kato, Koji

    AU - Hara, Shinya

    AU - Kawada, Jun ichi

    AU - Ito, Yoshinori

    PY - 2015/12/1

    Y1 - 2015/12/1

    N2 - A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.

    AB - A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.

    UR - http://www.scopus.com/inward/record.url?scp=84947493186&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84947493186&partnerID=8YFLogxK

    U2 - 10.1016/j.jiac.2015.08.005

    DO - 10.1016/j.jiac.2015.08.005

    M3 - Article

    C2 - 26390826

    AN - SCOPUS:84947493186

    VL - 21

    SP - 879

    EP - 881

    JO - Journal of Infection and Chemotherapy

    JF - Journal of Infection and Chemotherapy

    SN - 1341-321X

    IS - 12

    ER -